



## 9.00 -9.30 WELCOME AND INTRODUCTIONS George Sourvinos, Local Organiser - ESCV Pamela Vallely, President ESCV Heli Harvala, ENPEN-ESCV Thea Kølsen Fischer – ENPEN

## SESSION I – THE CURRENT STATE OF PLAY

- 9.30 10.00 **Eugene Victor Saxentoff, WHO Europe:** Clinical and supplementary enterovirus surveillance inEurope in the support of the Global Polio Eradication Initiative
- 10.00 10.15 Javier Martin, WHO Global Reference Laboratory: Importance of wastewater surveillance in identification of poliovirus in England
- 10.15 10.30 **Thea Kølsen Fischer, Denmark:** How ENPEN initiatives can supplement polio eradication

#### **COFFEE BREAK (30 MINS)**

## SESSION II – THE FUTURE OF ENTEROVIRUS SURVEILLANCE

- 11.00 11.15 **Sten de Schrijver, the Netherlands:** Circulation of enteroviruses in Europe, 2015-2023
- 11.15 11.30 Heli Harvala, England: The ENPEN-WHO EV surveillance study: what, when and why
- 11.30 11.45 **Caroline Klint Johannesen, Denmark:** Experience from hospital-based surveillance study
- 11.45 12.00 Jelte Helfferich, the Netherlands: AFM surveillance (on-line)
- 12.00-12.15 Kristina Franck, Denmark: Wastewater surveillance and non-polioviruses
- 12.15 13.00 **Discussion:** properties and requirements for future enterovirus surveillance

#### LUNCH BREAK (60 MINS)

#### SESSION III – TREATMENT OF ENTEROVIRUS INFECTIONS

- 14.00 14.30 Liam Reilly, Scotland: Current treatment options for severe enterovirus infections
- 14.30-14.40 Marta Butrym: Vemurafenib prevents CBV3 replication in cell models
- 14.40 15.45 Discussions: ENPEN plans for treatment database and guideline
- 16.00 23.00 CORFU TOUR AND DINNER





## 8.00 – 8.30 MORNING WALKING OR JOGGIN AT THE GARITSA GULF

#### SESSION IV – SEROPREVALENCE STUDIES AND DIAGNOSTIC ADVANCES

- 9.00 9.15 Karen Couderé, the Netherlands: Neutralising antibody testing betweenlaboratories
- 9.15 9.30 Alison Tedcastle, NIBSC: WHO International standards for non-polio enteroviruses
- 9.30 9.45 Kim Benschop, the Netherlands: Next Generation Sequencing for enterovirus typing
- 9.45 10.00 Maxine Bisseux, France: Deep sequencing of enterovirus through PCR-based enrichment
- 10.00 10.15 Nóra Deézsi-Magyar<sup>,</sup> Hungary: Metagenomic sequencing of parechoviruses
- 10.15 10.30 Emma Hodcroft, Switzerland: How to use NextStrain to enhance enterovirus surveillance?
- 10.30 10.40 Jean-Luc Bailly, France: Molecular epidemiology of EV-A71 in Europe
- 10.45 11.00 Natasa Berginc, Slovenia: Circulation of EV-C105 in Europe

#### **COFFEE BREAK 30 MINS**

- 11.00 12.00 Group working:
- TOPIC I what do we want to do next and why?
- TOPIC II What to consider when introducing NGS?
- 12.00 13.00 Conclusions and plan forward

LUNCH 60 MINS

14.00 – 15.00 FINAL CONCLUSIONS AND ACTIONS TO BE TAKEN HOME





## Kimberley S.M. Benschop

PhD, Molecular Virologist, Senior Project Coordinator Clinical EV and HBV Surveillance, Centre for infectious Disease Control (Cib),

Centre for Infectious Disease Research, Diagnostics and laboratory Surveillance (IDS),

Dutch National Institute for Public Health and the Environment, The Netherlands

#### Natasa Berginc

National Laboratory of Health, Environment and Food, Department for Public Health Microbiology, Slovenia

## Karen Couderé

MD, Medical Microbiologist, Microvida, Zorgsaam, ADRZ, PhD candidate Amsterdam UMC, The Netherlands

## Sten de Schrijver

Intern, National Institute for Public health and the Environment (RIVM), The Netherlands

#### Dr Heli Harvala

Consultant Medical Virologist, NHS Blood and Transplant, Colindale, Principal Investigator, University of Oxford, UK

## Jelte Helfferich

MD, PhD, Pediatric Neurologist, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

## **Caroline Klint Johannesen**

MSc, PhD student, North Zealand Hospital, Denmark

## Thea Kølsen Fischer

Professor, Public Health Virology, Director of Clinical Research, Nordsjællands Hospital - Part of Copenhagen University Hospital, Denmark

Dr Javier Martin

Principal Scientist, Head of WHO Global Specialized Laboratory for Polio, MHRA, Potters Bar, UK

#### **Dr Liam Reilly**

Consultant in Paediatric Immunology, Infectious Diseases, and Haematopoietic Stem Cell Transplant, Royal Hospital for Children, Glasgow, UK

#### **Eugene Saxentoff**

Ph.D., Polio Laboratory Network/Poliovirus Containment Coordinator, Vaccine-preventable Diseases and Immunization (VPI),

Division of Communicable Diseases, Environment and Health (CDE),

World Health Organization, European Region

## George Sourvinos

PhD, Professor of Clinical Virology,





Medical School, University of Crete, Head of the Laboratory of Clinical Virology, University Hospital of Crete, Heraklion, Crete, Greece

# Dr Alison Tedcastle

Virologist, Polio Group, MHRA, UK

**Pam Vallely** Professor of Medical Virology, University of Manchester, UK